2103399-35-3

Usage

Uses

Used in Pharmaceutical Industry:
(S)-5-fluoro-2,3-dihydro-1H-inden-1-amine hydrochloride is used as an appetite suppressant for the treatment of obesity. It functions by inhibiting the reuptake of serotonin and norepinephrine, leading to increased levels of these neurotransmitters in the brain, which helps to reduce appetite and promote weight loss.
However, it is important to note that due to concerns about its potential for cardiovascular side effects, sibutramine hydrochloride has been withdrawn from the market in many countries, and its use is now restricted or banned in several jurisdictions. As a result, the pharmaceutical applications of (S)-5-fluoro-2,3-dihydro-1H-inden-1-amine hydrochloride may be limited or non-existent in some areas.

Upstream product

• 101752-05-0 methanol hydrochloride 
• 700-84-5 5-fluoro-1-indanone 
• 148960-32-1 5-fluoro-1-indanone oxime 

Relevant academic research and scientific papers

CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.

COMPOUNS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

alpha-SUBSTITUTED GLYCINAMIDE DERIVATIVE

The present invention is to provide a novel α-substituted glycinamide derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. The present invention provides a compound represented by the general formula (I), which has TRPM8 inhibitory effects: [wherein A1 represents a C6-10 aryl and the like, A2 represents a C6-10 aryl and the like, X represents CH and the like, Y represents —CR1R2— and the like, R1 and R2 independently represent a hydrogen atom and the like, R3 and R4 independently represent a halogen atom and the like, n is 1 or 2], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing diseases or symptoms caused by hyperexcitability or disorder of afferent neurons.

[alpha]-substituted glycineamide derivative

The present invention provides: a novel [alpha]-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the [alpha]-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; and a use of the [alpha]-substituted glycineamide derivative or a pharmacologically acceptable salt thereof for medical purposes. The present invention provides a compound which has an inhibitory activity on TRPM8 and is represented by general formula (I) [wherein A1 represents a C6-10 aryl group or the like; A2 represents a C6-10 aryl group or the like; X represents CH or the like; Y represents -CR1R2- or the like; R1 and R2 independently represent a hydrogen atom or the like; R3 and R4 independently represent a halogen atom or the like; and n represents 1 or 2] or a pharmacologically acceptable salt thereof. The compound (I) according to the present invention can be used as a therapeutic or prophylactic agent for diseases or conditions associated with afferent nerve hyperexcitability or injury.

NOVEL TRPM8 INHIBITOR

PROBLEM TO BE SOLVED: To provide a novel α-substituted glycine amide derivative, or a pharmaceutical composition containing pharmacologically acceptable salt thereof, and a medicinal use thereof. SOLUTION: The present invention provides a compound expressed by a general formula (I) having TRPM8 inhibitory action (in the formula, A1 denotes C6-10 aryl or the like, A2 denotes C6-10 aryl or the like, X denotes CH or the like, Y denotes -CR1R2- or the like, R1 and R2 denote hydrogen atom or the like independently, R3 and R4 denote halogen atom or the like independently, and n denotes 1 or 2), or a pharmaceutical composition containing pharmacologically acceptable salt thereof. Furthermore, a pharmaceutical composition of the present invention is usable as treatment or a prophylactic drug of disease or symptom caused by hyperexcitement or disorder of afferent nerves. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Sulfonamide-substituted fused 5-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them

Compounds of the formula I having the meanings of the substituents indicated in the claims are outstandingly active substances for the production of medicaments for the prophylaxis and for the therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastro-intestinal region or for the treatment of diarrheal illnesses.